IAMOG
CRSP icon

Investors Asset Management of Georgia’s CRISPR Therapeutics CRSP Stock Holding History

Investors Asset Management of Georgia’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,300
Closed -$79K – 617
2022
Q2 		$79K Buy
+1,300
New +$76.4K 0.04% 221

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Investors Asset Management of Georgia's CRSP Position: Q3 2022 in Review

Investors Asset Management of Georgia sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 1,300 shares — an estimated $79K sold.

Investors Asset Management of Georgia first reported a position in CRSP in Q2 2022 and held it in 1 quarter. The position peaked at $79K in Q2 2022. 435 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • Investors Asset Management of Georgia reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 1,300 CRISPR Therapeutics shares in Q3 2022, an estimated $79K.
  • Investors Asset Management of Georgia first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 1 quarter.
  • Investors Asset Management of Georgia's CRISPR Therapeutics position peaked at $79K in Q2 2022.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Investors Asset Management of Georgia's 13F filing for Q3 2022, filed 27 Oct 2022.